Comparison of High-Dose versus Low-Dose Trimethoprim–Sulfamethoxazole for Treating Pneumocystis jirovecii Pneumonia among Hemodialysis Patients: A Nationwide Database Study in Japan
Journal of Clinical Medicine · 14.09.2024 · 13 (18) · 5463
DOI: 10.3390/jcm13185463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.09.2024. Verfasst von Hisayuki Shuto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Medicine and Infectious Diseases, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu 879-5593, Oita, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hemodialysis patients are at high risk for developing Pneumocystis jirovecii pneumonia (PJP), and trimethoprim–sulfamethoxazole (TMP–SMX) is the first-line agent for treating this disease. However, there is a lack of consensus on the required dosage of TMP–SMX for hemodialysis patients.
Methods
This study used the nationwide Japanese Diagnosis Procedure Combination database to review hemodialysis patients hospitalized for PJP from April 2014 to March 2022. Eligible patients were divided into high-dose and low-dose groups based on the median daily dose per body weight of TMP. The 90-day mortality and adverse events after propensity score matching were compared between the groups.
Results
A total of 126 hemodialysis patients with PJP were included, and the median daily dose per body weight of TMP was 5.74 mg/kg/day (interquartile range: 4.33–8.18 mg/kg/day). Thirty-two pairs were analyzed after the propensity score matching. No significant differences in the 90-day mortality and proportion of adverse events were observed between the high-dose and low-dose groups.
Conclusions
A high dose of TMP–SMX is unlikely to decrease the in-hospital mortality and adverse events among hemodialysis patients with PJP. However, the results should be interpreted with caution, given the lack of power and lack of long-term follow-up. Additional prospective interventional studies are required to validate these results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Respiratory Medicine and Infectious Diseases, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu 879-5593, Oita, Japan.
- Research Center for Global and Local Infectious Diseases, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu 879-5593, Oita, Japan.
- Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-ku 113-8519, Tokyo, Japan.
ORCID-Profile: Hisayuki Shuto, Shota Omori, Kosaku Komiya
Zitieren
APA
Shuto, H., Omori, S., Hiramatsu, K., Kadota, J. I., Fushimi, K., & Komiya, K. (2024). Comparison of High-Dose versus Low-Dose Trimethoprim–Sulfamethoxazole for Treating Pneumocystis jirovecii Pneumonia among Hemodialysis Patients: A Nationwide Database Study in Japan. Journal of Clinical Medicine, 13(18), 5463. https://doi.org/10.3390/jcm13185463
Vancouver
Shuto H, Omori S, Hiramatsu K, Kadota JI, Fushimi K, Komiya K. Comparison of High-Dose versus Low-Dose Trimethoprim–Sulfamethoxazole for Treating Pneumocystis jirovecii Pneumonia among Hemodialysis Patients: A Nationwide Database Study in Japan. Journal of Clinical Medicine. 2024;13(18):5463. doi:10.3390/jcm13185463
BibTeX
@article{Shuto2024,
author = {Shuto, Hisayuki and Omori, Shota and Hiramatsu, Kazufumi and Kadota, Jun-Ichi and Fushimi, Kiyohide and Komiya, Kosaku},
title = {Comparison of High-Dose versus Low-Dose Trimethoprim–Sulfamethoxazole for Treating Pneumocystis jirovecii Pneumonia among Hemodialysis Patients: A Nationwide Database Study in Japan},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {18},
pages = {5463},
doi = {10.3390/jcm13185463}
}
EUVIMED